Targeting the PD-1/PD-L1 axis in the treatment of lung cancer

Kategoria artykułu: Research Article

Data publikacji: 17 wrz 2016

Zakres stron: 17 - 27

Otrzymano: 16 lut 2016

Przyjęty: 16 lut 2016

DOI: https://doi.org/10.1515/fco-2015-0021

Słowa kluczowe

NSCLC, PD-1, PD-L1, Nivolumab, Pembrolizumab

© 2016

This article is distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.